

AD_____

Award Number: W81XWH-11-1-0541

TITLE: Pro-lipogenic action of lysophosphatidic acid in ovarian cancer

PRINCIPAL INVESTIGATOR: Xianjun Fang

CONTRACTING ORGANIZATION: Virginia Commonwealth University
Richmond, VA 23219-1441

REPORT DATE: April 2014

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE April 2014		2. REPORT TYPE Final		3. DATES COVERED 1 July 2011-30 December 2013	
4. TITLE AND SUBTITLE Pro-lipogenic action of lysophosphatidic acid in ovarian cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-11-1-0541	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Xianjun Fang E-Mail: xfang@vcu.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Virginia Commonwealth University 737 N 5th Street, Ste 100 Richmond, VA 23219-1441				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The objective of the project was to determine the role of endogenous lysophosphatidic acid (LPA) in lipogenesis and metabolic abnormalities of ovarian cancer cells. We found that LPA upregulated <i>de novo</i> lipogenesis in ovarian cancer cells. We showed this effect of LPA is physiologically relevant by demonstrating the pro-lipogenic activity of endogenous levels of LPA. Suppression of the LPA-producing enzyme iPLA2 β strongly inhibited proliferation of ovarian cancer cells, an effect not reversed by the presence of LPA. Our results indicate the importance of fatty acid catabolism through β oxidation in promotion of ovarian cancer cell growth and survival. Since we have shown that LPA-driven lipogenesis is required for proliferation of ovarian cancer cells, our results together establish a dual role for lipid metabolism (anabolism and catabolism) in maintenance of the malignant phenotype of ovarian cancer cells. The results from this pilot study have led to one publication in JBC and another manuscript in preparation. Built on the results of the study, we are also preparing an R01 grant application for submission to NIH/NCI in February of 2014.					
15. SUBJECT TERMS Ovarian cancer, LPA, lipid metabolism, metabolic abnormality, iPLA2, fatty acids					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	30	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	7
Reportable Outcomes.....	8
Conclusion.....	9
References.....	10
Appendices.....	11-30

Final Progress Report for W81XWH-11-1-0541

Introduction

Ovarian cancer and other human malignancies show aberrant lipid metabolism. The current ovarian cancer pilot research project titled “Pro-lipogenic action of lysophosphatidic acid in ovarian cancer” was to determine the role of endogenous lysophosphatidic acid (LPA) in lipogenesis and metabolic abnormalities of ovarian cancer cells. We proposed to study the role of endogenous LPA in regulation of lipogenesis in ovarian cancer cells (Aim 1), and the contribution of LPA-driven lipogenesis to metabolic abnormalities of ovarian cancer cells (Aim 2). The details of the progresses are provided below.

Body of Research Report

Specific Aims:

Aim 1. To define the role of endogenous LPA in regulation of lipogenesis in ovarian cancer cells

1.1 Examination of whether LPA in serum and LPA-inducing agents are sufficient to induce lipogenesis in ovarian cancer cells

We examined whether serum stimulates *de novo* lipid synthesis in ovarian cancer cells (1). Serum strongly induced lipogenesis in OVCA-432 and Caov-3 cells. We have identified the LPA2 receptor as the primary receptor responsible for the lipogenic action of LPA as detailed in Fig. 5 of Appendix I. LPA stimulated endogenous lipogenesis via its receptor subtype 2 (LPA2). LPA2 was linked to Gq and G12/13 to activate the AMPK-ACC and SREBP-FAS pathway, respectively (Fig. 6 of Appendix I). The selective role of LPA2 in LPA-mediated activation of lipogenesis enabled us to determine whether biological fluids such as serum at physiological concentrations could promote lipogenesis via its constituent LPA. Knockdown of LPA2 expression not only inhibited LPA-induced lipogenesis (Fig. 5 of Appendix I) but also significantly attenuated serum-driven lipogenesis (Fig. 1), suggesting that LPA is a major constituent of serum to promote lipogenesis in ovarian cancer cells.

1.2 Assessment of the effects of manipulating LPA-producing enzyme autotaxin on activation of lipogenic pathways and *de novo* lipid synthesis in ovarian cancer cells.

Autotaxin is one of the LPA-generating enzymes (2, 3). We have produced recombinant autotaxin protein from HEK293 cells. The recombinant protein is enzymatically and biologically active as we reported previously (3). Incubation of ovarian cancer cell lines with recombinant autotaxin and its enzymatic substrate lysophosphatidylcholine (LPC, 5 μ M) increased *de novo* lipogenesis as shown in Fig. 2. However, siRNA downregulation of autotaxin did not significantly attenuate lipogenic activity, suggesting that endogenously expressed autotaxin is not a critical mediator of LPA production and lipid synthesis in ovarian cancer cells (Fig. 2). Due to this negative impact of autotaxin, we have placed our focus on the alternative LPA-producing enzyme iPLA2, which has led to novel and interesting findings (see Task 1.3, and Task 2.2).

1.3 Assessment of the effects on lipogenic enzymes and lipogenesis of pharmacological and molecular inhibition of iPLA2, another enzyme involved in LPA production in ovarian cancer cells.

Because several groups have recently reported that PLA2 enzymes mediate LPA production and cell growth in various cancer cells including ovarian cancer (4-6), we investigated the molecular mechanism underlying the effect of iPLA2 in ovarian cancer cells. The results of this line are summarized together with Task 2.2 which addresses the importance of the supply of fatty acids, another metabolite of iPLA2 β activity (see Task 2.2).

Aim 2. To determine the contribution of LPA-driven lipogenesis to metabolic abnormalities of ovarian cancer cells:

2.1 Analysis of the effects of LPA and LPA production on mitochondrial respiration in ovarian cancer cells

Intracellular ATP levels were analyzed as function of mitochondrial respiration. Increased ATP production would decrease AMP/ATP ratio, which could provide explanation of how LPA inactivates AMPK (see Fig. 3 of Appendix I). We initially tried the luciferin/luciferase method to measure ATP. Although straightforward and reportedly to be quantitative (7), we found that the approach was largely qualitative with significant variations from experiment to experiment. We then switched to an HPLC-based assay which was more accurate and reproducible. Treatment of ovarian cancer cell lines with

LPA increased ATP levels and decreased AMP/ATP ratio (Fig. 3).

2.2 Elucidation of the role of LPA and LPA production in regulation of lipid catabolic enzymes including monoacylglycerol lipase (MAGL) and fatty acid β oxidation

LPA could be produced by activity of iPLA β . However, these enzymes such as iPLA2 β could also lead to release and accumulation of fatty acids, byproduct of LPA biosynthesis. Exogenous fatty acids enhanced proliferative responses of ovarian cancer cells to growth factors, suggesting that fatty acid availability promotes β oxidation and cell proliferation (Fig. 4). This hypothesized role of fatty acids from phospholipases is consistent with our previous observation that exogenously supplemented LPA did not fully reverse the effect of the iPLA2 β inhibitor BEL on cell cycling (8), suggesting involvement of additional bioactive mediator of iPLA2 β .

Regulation of fatty acid availability may represent a critical but previously unrecognized function of iPLA2 β . To test this, we used shRNA knockdown or pharmacological inhibition of several enzymes involved in lipolysis and fatty acid β -oxidation. Inhibition of iPLA2 β with a dominant-negative form was found to inhibit growth of ovarian cancer cell lines (Fig. 5). Furthermore, inhibition of carnitine palmitoyl transferase 1A (CPT1A) with a specific inhibitor etomoxir (9) or shRNA suppressed cell growth in most ovarian cancer cell lines (Fig. 6A, 6B). CPT1 is the rate-limiting enzyme of β oxidation responsible for shuttling long-chain fatty acids into the mitochondrial matrix (10). Etomoxir or shRNA knockdown of CPT1A had limited effect on cell viability (Fig. 7A, 7B). However, combination of etomoxir with ABT263, a BH3 mimetic inhibitor of the Bcl2 family members (11) resulted in synergistic induction of apoptosis (Fig. 7A, 7B & Fig. 8), suggesting that CPT1A is also involved in cytoprotection of ovarian cancer cells from anti-cancer drugs. Importantly, CPT1A was overexpressed in ovarian cancer cell lines (Fig. 8, *upper*). The sensitivity of ovarian cancer cell lines to apoptosis induced by the combined treatment with etomoxir and ABT263 correlated with the CPT1A expression levels in these cells (Fig. 8, *lower*). Taken together, these results indicate that iPLA2 β contribute to ovarian oncogenesis via not only generation of LPA but also enhancement of fatty acid oxidation.

2.3 Determination of the effects of LPA signaling on cholesterol synthesis and structures and functions of lipid rafts

LPA stimulated expression of the cholesterol synthesis rate-limiting enzyme HMG-CoA reductase via activation of SREBP (Fig. 2 of Appendix I). Consistent with HMG-CoA upregulation, we found that LPA increased cellular cholesterol levels (Fig. 9). The result indicates that LPA could signal to regulate functions of lipid rafts by modulating the biosynthesis of cholesterol, a principal structural component of lipid rafts (12).

2.4 Metabolic profiling of alterations in membrane and cellular lipids modulated by LPA using mass spectrometry

The total and major classes of lipids (neutral, phospholipids and cholesterol) were elevated in LPA-treated ovarian cancer cells (Fig. 4 of Appendix I & Fig. 9). During the second year of the grant support, my graduate student Abir Mukherjee received training with mass spectrometry (MS). After his graduation, the remaining fund of grant was limited and not adequate for me to hire him as a post-doc fellow to continue the study. During the no-cost extension period, I assigned another graduate student Fang Yuan to work part-time on the task. Unfortunately, for a student without prior research experience in lipid biology and MS, the development of the technique took longer than I originally thought. We will continue the effort by seeking alternative funding support in the future.

Key Research Accomplishments

- LPA is an endogenous factor to promote lipogenesis in ovarian cancer cells (Task 1.1);
- Autotaxin does not play a major role in LPA production and lipogenesis in ovarian cancer cells as we originally hypothesized (Task 1.2);
- iPLA2 β is a critical mediator of LPA production, fatty acid catabolism and proliferation of ovarian cancer cells (Task 1.3)
- LPA upregulates ATP production, a potential mechanism to inactivate AMPK (Task 2.1);
- Regulation of fatty acid availability and β oxidation represents a critical but previously unrecognized functional aspect of the LPA-producing enzyme iPLA2 β (Task 2.2);
- CPT1A, a rate-limiting enzyme in fatty acids oxidation, is overexpressed in ovarian cancer cell lines and regulates cellular proliferation and survival (Task 2.2);
- LPA stimulates HMG-CoA reductase expression and cholesterol synthesis in ovarian cancer cells (Task 2.3);

Reportable Outcomes

Manuscript published:

Mukherjee A, Wu J, Barbour S and Fang X. Lysophosphatidic acid activates lipogenic pathways and *de novo* lipid synthesis in ovarian cancer cells. J Biol. Chem. 2012 287:24990-5000. PMID: 22665482

Abstracts and meeting presentation:

Mukherjee A, Wu J, Barbour S, and Fang X. Lysophosphatidic acid is a novel regulator of *de novo* lipogenesis in ovarian cancer. AACR special conference: Metabolism and Cancer. October 16-19, 2011, Baltimore, MD

Manuscript in preparation:

Shao H, Mukherjee A, Yuan F, Kai J, and Fang X. Carnitine palmitoyl transferase 1A promotes proliferation and survival of ovarian cancer cells. Manuscript in preparation.

Conclusions

In this pilot study, we found that LPA upregulated *de novo* lipogenesis in ovarian cancer cells. We showed this effect of LPA is physiologically relevant by demonstrating the pro-lipogenic activity of endogenous levels of LPA. Suppression of the LPA-producing enzyme iPLA2 β strongly inhibited proliferation of ovarian cancer cells, an effect not reversed by the presence of LPA. Our results indicate the importance of fatty acid oxidation in promotion of ovarian cancer cell growth and survival. Since we have shown that LPA-driven lipogenesis is required for proliferation of ovarian cancer cells, our results together establish a dual role for lipid metabolism (anabolism and catabolism) in maintenance of the malignant phenotype of ovarian cancer cells. The results from this pilot study have led to one publication in JBC and another manuscript in preparation. Built on the results of the study, we are also preparing an R01 grant application for submission to NIH/NCI in February of 2014.

References Cited

1. Mukherjee A, Wu J, Barbour S and **Fang X**. Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells. *J Biol. Chem.* 2012. 287: 24990-25000.
2. Umezū-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, and Arai H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. *J Cell Biol.* 2002. 158: 227-233.
3. Song Y, Dilger E, Bell J, Barton WA, and Fang X. Large scale purification and characterization of recombinant human autotaxin/lysophospholipase D from mammalian cells. *BMB Rep.* 2010 43: 541-546.
4. Surrel F, Jemel I, Boilard E, Bollinger JG, Payré C, Mounier CM, Talvinen KA, Laine VJO, Nevalainen TJ, Gelb MH, and Lambeau G. Group X phospholipase A2 stimulates the proliferation of colon cancer cells by producing various lipid mediators. *Mol. Pharmacol.* 2009. 76: 778–790, 2009.
5. Cai Q, Zhao Z, Antalis C, Yan L, Del Priore G, Hamed AH, Stehman FB, Schilder JM, and Xu Y. Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancer. *FASEB J.* 2012. 26: 3306-3320.
6. Li H, Zhao Z, Wei G, Yan L, Wang D, Zhang H, Sandusky GE, Turk J, and Xu Y. Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development. *FASEB J.* 2010. 24: 4103-4116.
7. Corey MJ, Kinders RJ, Brown LG, and Vessella RL. A very sensitive coupled luminescent assay for cytotoxicity and complement-mediated lysis. *J. Immunol Methods.* 1997 207: 43-51.
8. Song Y, Wilkins P, Hu W, Karnam M, Chen J, Lee Z, Oyesanya R, Barbour S, and **Fang X**. Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells. *Biochem J.* 2007. 406: 427-436.
9. Spurway T. D, Pogson CI, Sherratt HAS, and Agius L. Etomoxir, sodium 2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate, inhibits triacylglycerol depletion in hepatocytes and lipolysis in adipocytes. *FEBS Letters*, 1997. 404: 111-114.
10. Zammit, VA. Carnitine Palmitoyltransferase 1: Central to Cell Function. *IUBMB Life.* 2008. 60: 347-354.
11. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, and Elmore SW. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. *Cancer Res.* 2008. 68: 3421-3428.
12. Lindner R, and Naim HY. Domains in biological membranes. *Exp. Cell Res.* 2009. 315: 2871-2878.




Fig. 1. Knockdown of the LPA2 receptor prevents lipogenesis of ovarian cancer cells cultured in complete medium containing 10% FBS. LPA2 in OVCA-432 cells was stably knocked down by lentivirally transduced shRNA (LPA2sh). The *de novo* lipogenesis was quantified as described in Appendix I and the lipogenic activity was compared with the cells transduced with control shRNA (Csh).




Fig. 2. Knockdown of endogenous autotaxin does not inhibit lipogenesis in OVCA-432 cells. In *left*, Caov-3 cells were incubated in serum-free medium supplemented with LPC (1-oleoyl, 5 μ M, substrate of autotaxin) or LPC+autotaxin (recombinant protein, 100 ng/ml) for 48 hours before analysis of *de novo* lipogenesis as detailed in Appendix I. In *right*, lipogenesis in autotaxin siRNA knockdown cells was determined and compared with that in control siRNA-treated cells. The data of both panels were presented as fold change relative to the values of control cells which were defined as 1 arbitrary unit.




Fig. 3. Treatment of ovarian cancer cell lines with LPA increased ATP production and decreased AMP/ATP ratio. Caov3 cells were serum starved overnight prior to LPA (10 mM) treatment for 12 hours. Nucleotides were extracted and analyzed with HPLC.




Fig. 4. Palmitate potentiates LPA-induced growth of ovarian cancer cells. Caov-3 cells were incubated with or without LPA in serum-free medium supplemented with the indicated Concentrations of palmitate. The cell numbers were determined with coulter counter after 48 hours.




Fig. 5. Inhibition of iPLA2 activity and cell growth by stable expression of the dominant negative iPLA2b (M10iPLA2b) in SKOV-3 cells. Western blot analysis confirmed expression of the mutant in two clones (#clone #7 and #10)(*upper left*). The cellular activity was inhibited by the mutant in both clones (*lower left*). The growth curves of the control and clone #10 in serum-free conditions were determined by crystal violet staining (*right*).






Fig. 6A. CPT1A is required for growth of ovarian cancer cell lines. CPT1A in SKOV-3 and OVCA-432 cells was down-regulated by two independent shRNAs. One (sh-CPT1A-2) completely eliminated CPT1A expression while the other (sh-CPT1A-1) partially inhibited CPT1A (lower panel). The growth curves showed a dose-dependent inhibition of SKOV-3 and OVCA-432 cell growth by shRNA knockdown of CPT1A.




Fig. 6B. CPT1A is required for growth of ovarian cancer cell lines. SKOV-3 and OVCA-432 cells were culture with etomoxir (0.3 mM) or vehicle (ctrl) for the indicated periods of time (Days). The number of cells were determined daily With a Coulter counter.




Fig. 7A. Co-treatment with etomoxir and ABT263 induced synergistic apoptosis in SKOV-3 and OVCA-432. The cells were treated with ABT263, etomoxir or their combination (Comb) for 24 hours. The percentages of apoptotic cells (presented in each panel) were determined by flow cytometry quantification of Annexin V-positive, apoptotic cells.




Fig. 7B. Co-treatment with etomoxir and ABT263 induced synergistic apoptosis in SKOV-3 and OVCA-432 cells. Shown was immunoblotting analysis of apoptosis-associated cleavage of caspase 3 in cells treated with ABT263, etomoxir or their combination (Comb) for 24 hours at the indicated concentrations.




Fig. 8. CPT1A, but not CPT1C, is overexpressed in ovarian cancer cell lines (*upper*), which correlates with the sensitivity of the cells to apoptosis induced by combination (Comb) of etomoxir (0.3 mM) and ABT-263 (1 μ M) (*lower*).




Fig. 9. LPA and EGF increases cholesterol levels in Caov-3 cells. The cells were treated with LPA (10 μ M) or EGF (20 ng/ml) for 24 hours before quantification of cellular cholesterol contents with a kit from Cell Biolabs, Inc. The data were presented as fold increase relative the cholesterol level in the un-stimulated control cells (BSA).

Lysophosphatidic Acid Activates Lipogenic Pathways and *de Novo* Lipid Synthesis in Ovarian Cancer Cells*

Received for publication, January 9, 2012, and in revised form, May 31, 2012. Published, JBC Papers in Press, June 3, 2012, DOI 10.1074/jbc.M112.340083

Abir Mukherjee, Jinhua Wu, Suzanne Barbour, and Xianjun Fang¹

From the Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, School of Medicine, Richmond, Virginia 23298

Background: Mechanisms underlying the lipogenic phenotype of cancer cells are poorly understood.

Results: Lysophosphatidic acid (LPA) via its receptor LPA₂ activates lipogenic pathways and *de novo* lipid synthesis in ovarian cancer cells.

Conclusion: LPA is causally linked to the aberrant lipogenesis in cancer.

Significance: This study offers a new strategy to inhibit lipid anabolism in a cancer cell-specific manner.

One of the most common molecular changes in cancer is the increased endogenous lipid synthesis, mediated primarily by overexpression and/or hyperactivity of fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC). The changes in these key lipogenic enzymes are critical for the development and maintenance of the malignant phenotype. Previous efforts to control oncogenic lipogenesis have been focused on pharmacological inhibitors of FAS and ACC. Although they show anti-tumor effects in culture and in mouse models, these inhibitors are non-selective blockers of lipid synthesis in both normal and cancer cells. To target lipid anabolism in tumor cells specifically, it is important to identify the mechanism governing hyperactive lipogenesis in malignant cells. In this study, we demonstrate that lysophosphatidic acid (LPA), a growth factor-like mediator present at high levels in ascites of ovarian cancer patients, regulates the sterol regulatory element binding protein-FAS and AMP-activated protein kinase-ACC pathways in ovarian cancer cells but not in normal or immortalized ovarian epithelial cells. Activation of these lipogenic pathways is linked to increased *de novo* lipid synthesis. The pro-lipogenic action of LPA is mediated through LPA₂, an LPA receptor subtype overexpressed in ovarian cancer and other malignancies. Downstream of LPA₂, the G_{12/13} and G_q signaling cascades mediate LPA-dependent sterol regulatory element-binding protein activation and AMP-activated protein kinase inhibition, respectively. Moreover, inhibition of *de novo* lipid synthesis dramatically attenuated LPA-induced cell proliferation. These results demonstrate that LPA signaling is causally linked to the hyperactive lipogenesis in ovarian cancer cells, which can be exploited for development of new anti-cancer therapies.

One of the most common molecular changes in tumor cells is the heightened rate of *de novo* lipid synthesis compared with

their normal counterparts. The aberrant lipogenesis in cancer cells is mediated by increased expression and activity of key lipogenic enzymes, primarily fatty acid synthase (FAS)² and acetyl-CoA carboxylase (ACC). Interestingly, the alterations in these key lipogenic enzymes are critical for the development and maintenance of the malignant phenotype (1). It occurs at early stages of tumorigenesis and becomes more pronounced in advanced cancers (1, 2). Overexpression of FAS correlates with poor prognosis in several types of human malignancies, including ovarian cancer (3, 4). Furthermore, tumor cells depend heavily on or are “addicted” to *de novo* lipid synthesis to meet their energetic and biosynthetic needs, irrespective of the nutritional supplies in the circulation (1). Consistent with this, pharmaceutical inhibitors of FAS suppress tumor cell proliferation and survival and enhance cytotoxic killing by therapeutic agents (5–10). However, one barrier to cancer patient applications of these inhibitors is their nonselective suppression of fatty acid synthesis in both normal and malignant tissues, which could deteriorate weight loss, anorexia, fatigue, and other cancer-associated complications. To target lipid anabolism in tumors specifically, it is important to identify the mechanism for the hyperactive lipogenesis in cancer cells, which is, however, poorly understood.

Lysophosphatidic acid (LPA), the simplest phospholipid, has long been known as a mediator of oncogenesis (11). LPA is present at high levels in ascites of ovarian cancer patients and other malignant effusions (11–13). LPA is a ligand of at least six G protein-coupled receptors (14). The LPA₁/Edg2, LPA₂/Edg4, and LPA₃/Edg7 receptors are members of the endothelial differentiation gene (Edg) family, sharing 46–50% amino acid sequence identity (14). GPR23/P2Y9/LPA₄ of the purinergic receptor family, and the related GPR92/LPA₅ and P2Y5/LPA₆ have been identified as additional LPA receptors, which are structurally distant from the LPA_{1–3} receptors (14, 15). The Edg LPA receptors, in particular LPA₂, is overexpressed in many types of human malignancies, including ovarian cancer (11, 16). Strong evidence implicates LPA₂ in the pathogenesis of ovar-

* This work was supported, in whole or in part, by National Institutes of Health Grants 2R01CA102196 and R21CA161478 from NCI (to X. F.). This work was also supported by Department of Defense Ovarian Cancer Research Program Grant W81XWH-11-1-0541 (to X. F.) and The Jeffress Memorial Fund award (to X. F.).

¹ To whom correspondence should be addressed. Tel.: 804-8280787; Fax: 804-828-1473; E-mail: xfang@vcu.edu.

² The abbreviations used are: FAS, fatty acid synthase; ACC, acetyl-CoA carboxylase; LPA, lysophosphatidic acid; AMPK, AMP-activated kinase; SREBP, sterol regulatory element-binding protein; qPCR, quantitative PCR; TAG, triacylglycerol.

ian, breast, and intestine tumors (16–18), although the exact oncogenic processes involved remain elusive.

In this study, we observed that LPA stimulated proteolytic activation of two isoforms of the sterol regulatory element-binding proteins (SREBPs), transcription factors involved in regulation of FAS and other lipogenic enzymes for biosynthesis of fatty acid and cholesterol. In addition, LPA induces dephosphorylation of AMPK α at Thr-172 and concomitant dephosphorylation of ACC at Ser-79. The dephosphorylation of ACC at Ser-79 is associated with activation of the enzyme (19). These LPA-induced changes in the lipogenic enzymes occurred hours after exposure to LPA, and the effects were sustained for many hours. Consistent with LPA activating these lipogenic pathways, LPA increased *de novo* lipid synthesis. We identified LPA₂, the receptor subtype overexpressed in ovarian cancer and other human malignancies, as the key receptor responsible for delivery of the lipogenic effect of LPA. The intracellular G_{12/13}-Rho signaling cascade is critical for LPA activation of the SREBP, whereas G_q-PLC is involved in LPA-mediated dephosphorylation and inhibition of AMPK. These findings reveal a novel mode of the cancer cell-specific regulation of lipogenesis by an intercellular factor present in the circulation and tumor microenvironments.

EXPERIMENTAL PROCEDURES

Reagents—LPA (1-oleoyl, 18:1) was obtained from Avanti Polar Lipids, Inc. (Alabaster, AL). Prior to use, LPA was dissolved in PBS containing 0.5% fatty acid-free bovine serum albumin (BSA) purchased from Roche Applied Science. Acetic acid (1-¹⁴C) was obtained from Moravsek Biochemicals (Brea, CA). Plasmid DNA was purified using the endo-free purification kit from Qiagen (Valencia, CA). The transfection reagent Dharmafect 1 was obtained from Dharmacon, Inc. (Lafayette, CO), and TransIT-TKO was obtained from Mirus Bio (Madison, WI). Luciferase assay reagents were obtained from Promega (Madison, WI). Anti-SREBP-1 and anti-SREBP-2 antibodies were obtained from BD Biosciences. Anti-phospho-AMPK α (Thr-172), anti-AMPK α , anti-phospho-ACC (Ser-79), anti-ACC, and anti-FAS antibodies were obtained from Cell Signaling (Danvers, MA). Anti-tubulin antibody was obtained from EMD4Biosciences (Gibbstown, NJ). BODIPY 493/503 and cell culture reagents were purchased from Invitrogen. The TaqMan Universal PCR Master Mix and qPCR probes for LPA₁, LPA₂, LPA₃, 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, and GAPDH were obtained from Applied Biosystems (Carlsbad, CA). Calpain I inhibitor, water-soluble cholesterol, the FAS inhibitor C75, the ACC inhibitor TOFA, and sodium palmitate were purchased from Sigma.

Cell Culture—The sources of ovarian cancer cell lines used in the study were described previously (20). These cells were cultured in RPMI medium supplemented with 10% FBS, 100 units/ml penicillin, and 100 μ g/ml streptomycin. IOSE-29 was originally obtained from Dr. N. Auersperg (University of British Columbia, Canada) and cultured as described previously (21).

siRNA, Plasmids, and Transfection—The siRNA oligos for LPA₁, LPA₂, LPA₃, and FAS were obtained from Applied Biosystems. These siRNAs were transfected into cells using Dharmafect 1 following the manufacturer's protocol. In brief, cells

were plated in 6-well plates to reach 50–60% confluence before transfection. Cells were then transfected with target-specific siRNA or nontargeting control siRNA (150 pM) with Dharmafect 1 (4 μ l) for 12–16 h. Approximately 48 h post-transfection, the cells were serum-starved overnight before LPA treatment. Lentiviruses carrying short hairpin RNA (shRNA) for LPA_{1–3} receptors were kind gifts from Dr. S. Huang (Medical College of Georgia) (22). The expression vector pcDNA3 expressing the dominant negative form of G_i was provided by Dr. P. Hylemon (Virginia Commonwealth University) (23, 24). The G_q and G₁₂ cDNAs were provided by Dr. R. D. Ye (University of Illinois at Chicago). The dominant negative mutants of G_q (G208A) and G₁₂ (G228A) (25–27) in pcDNA3 were made using the QuikChange XL site-directed mutagenesis kit (Stratagene, Santa Clara, CA). The plasmids and the vectors expressing N19Rho and botulinum toxin C3 were described previously (28, 29). These plasmids were transfected into ovarian cancer cell lines using Lipofectamine LTX Plus (Invitrogen) following the manufacturer's instruction.

Luciferase Assays—The SREBP-responsive luciferase reporter vector (pGL2-3 $\times$ SREBP-TK-Luc) was generated by cloning three repeats of the SREBP consensus sequence (AAAATCACCCCACTGCAAACCTCCCTCTGC) (30, 31) into the NheI and HindIII sites in front of the herpes simplex virus thymidine kinase gene promoter (–35 to +50) in the pGL2-TK-Luc vector (32). Ovarian cancer cell lines were transfected with the luciferase vector using TransIT-TKO according to the manufacturer's protocol. About 48 h after transfection, the cells were starved overnight and treated with LPA or vehicle (BSA) for 12 h. Cell extracts were prepared and assayed for luciferase activity using the luciferase assay kits from Promega.

Western Blotting—Cells were lysed as described previously (33). Total cellular proteins were resolved by SDS-PAGE, transferred to immunoblot membrane (polyvinylidene difluoride) (Bio-Rad), and immunoblotted with antibodies following the protocols of the manufacturers. Immunocomplexes were visualized with an enhanced chemiluminescence detection kit from Amersham Biosciences.

Quantitative PCR (qPCR)—Total cellular RNA was isolated from cultured cells using TRIzol (Invitrogen). Complementary DNA (cDNA) was synthesized using the High-Capacity cDNA reverse transcription kit (Applied Biosystems). The relative levels of LPA₁, LPA₂, LPA₃, HMG-CoA reductase, and GAPDH were determined by qPCR using gene-specific probes, the TaqMan Universal PCR master mix, and the Applied Biosystems 7900HT real time PCR system.

Measurement of *de Novo* Lipid Synthesis—Cells were grown in 6-well plates and serum-starved prior to treatment with LPA or vehicle for 24 h. The cells were labeled with [¹⁴C]acetic acid (5 μ Ci/ml) for the last 6 h of incubation. The cells were then washed twice with PBS and lysed with lysis buffer (25 mM HEPES, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 0.2 mM EDTA, 0.5% sodium deoxycholate, 20 mM glycerophosphate, 1 mM sodium vanadate, 1 mM PMSF, 10 μ g/ml leupeptin, and 10 μ g/ml aprotinin). Lipids were extracted using a chloroform/methanol solution (2:1). Phase separation was achieved by centrifugation at 3200 $\times$ g for 10 min. The organic phase was extracted and dried with a speed vacuum. Lipids were dissolved

LPA Activates Lipogenesis in Ovarian Cancer Cells

in Ultima Gold Mixture (PerkinElmer Life Sciences) and counted using Beckman LS 6500 scintillation counter. Each measurement was performed in triplicate and normalized to cell numbers.

Lipid Staining—Cells were grown and serum-starved prior to treatment with LPA or vehicle for 24 h. Cells were then stained with BODIPY 493/503 at a final concentration of 0.5 $\mu\text{g}/\text{ml}$ in PBS at 37 °C for 30 min, followed by counter-staining with Hoechst (10 $\mu\text{g}/\text{ml}$) for 15 min. Cells were then fixed with 2% paraformaldehyde and visualized with fluorescence microscopy.

Quantification of Triacylglycerols (TAG) and Phospholipids—TAG and phospholipids were extracted and quantified with the EnzyChrom triglyceride assay kit and the EnzyChrom phospholipid assay kit (BioAssay Systems, Hayward, CA), respectively, according to the manufacturer.

Statistics—All numerical data were presented as means $\pm$ S.D. The statistical significance of differences was analyzed using Student's *t* test, where $p < 0.05$ was considered statistically significant. In all figures, the statistical significances were indicated with an asterisk if $p < 0.05$ or two asterisks if $p < 0.01$.

RESULTS

LPA Induces Proteolytic Cleavage and Activation of SREBP in a Cholesterol-sensitive Manner—The hyperactive lipogenesis is a hallmark of tumor cells (1, 34). To identify pathophysiological mechanisms driving the lipogenic program in cancer cells, we examined the potential role of LPA, an endogenous regulator of many cellular functions in ovarian cancer and other human malignancies. We first assessed whether LPA was capable of activating the SREBP transcription factors that play crucial roles in regulating expression of lipogenic enzymes. Treatment of Caov-3, OVCA-432, and other ovarian cancer cell lines, including OVCAR-3, with LPA induced cleavage of the precursor forms of SREBP-1 and SREBP-2 in a time-dependent manner (Fig. 1A). The cleaved mature forms of SREBP-1 and SREBP-2 were detectable at 4 h and peaked at 12 h post-LPA treatment. In contrast to the ovarian cancer cell lines, LPA failed to activate SREBP-1 or SREBP-2 in the immortalized ovarian surface epithelial cell line IOSE-29 (Fig. 1A) or normal ovarian epithelial cells (data not shown), suggesting a cancer cell-specific mechanism for SREBP activation by LPA in ovarian cancer cells.

In physiological conditions, SREBP-1 and SREBP-2 are regulated by the intracellular sterol content. In their precursor forms, SREBPs are attached to the endoplasmic reticulum. Specific signaling cues such as reduced cholesterol levels trigger SREBP cleavage-activating protein (SCAP)-mediated transport of SREBP from endoplasmic reticulum to Golgi, where they are cleaved by proteases S1P and S2P to release the mature/active form (35). At high sterol concentrations, the SREBP-SCAP complex is retained in the endoplasmic reticulum due to increased binding to INSIG proteins (36). To determine whether LPA activation of SREBP could bypass cholesterol regulation, we preloaded Caov-3 and OVCA-432 cells with cholesterol (10 $\mu\text{g}/\text{ml}$) complexed with 0.1% fraction V fatty acid-free BSA in PBS, and then assessed activation of SREBP-1 in




FIGURE 1. LPA activates SREBP in ovarian cancer cells. Ovarian cancer cell lines and IOSE-29 cells were treated with LPA (10 μM) for indicated periods of time. The calpain inhibitor I (25 $\mu\text{g}/\text{ml}$) was added to cells for the last 2 h. Expression of SREBP-1 and SREBP-2 was analyzed by immunoblotting with antibodies that recognize both precursor (p) and active/mature (m) forms of SREBP-1 and SREBP-2 (A). B, Caov-3 and OVCA-432 cells were preloaded with or without cholesterol (10 $\mu\text{g}/\text{ml}$). The cells were treated with LPA and analyzed for expression of precursor and mature forms of SREBP as in A. C, Caov-3 and OVCA-432 cells were transfected with pGL2-3 $\times$ SREBP-TK-Luc and loaded with or without cholesterol before stimulation with LPA (10 μM) for 12 h. The luciferase activity in cell extracts was determined as described under "Experimental Procedures," and the results are presented as relative luciferase units (RLU).

response to LPA. As shown in Fig. 1B, cholesterol treatment reduced both basal and LPA-induced active SREBP-1 levels, indicating that activation of SREBP by LPA remains sensitive to the cholesterol availability.

To determine whether LPA-induced SREBP cleavage is sufficient to activate SREBP transcriptional activity, Caov-3 and OVCA-432 cells were transfected with the SREBP-responsive reporter pGL2-3 $\times$ SREBP-TK-Luc. As shown in Fig. 1C, treatment of transfected cells with LPA significantly enhanced luciferase activity in these cells. Similar to the SREBP cleavage, SREBP-dependent luciferase activity was also sensitive to cholesterol treatment (Fig. 1C).




FIGURE 2. LPA induces expression of the SREBP target genes FAS, ACC, and HMG-CoA reductase. Caov-3, OVCA-432, and OVCAR-3 cells were treated with or without LPA (10 μ M) for 16 h prior to immunoblotting analysis of FAS and ACC (A). Total cellular RNA was isolated from parallel samples and subjected to qPCR analysis of expression of HMG-CoA reductase mRNA (B). The results are presented as fold increase relative to the value in the vehicle-treated cells (defined as 1).

LPA Induces Expression of SREBP Target Genes FAS, ACC, and HMG-CoA Reductase—To substantiate the biological significance of SREBP activation by LPA, we monitored expression levels of FAS, ACC, and HMG-CoA reductase. These are well known targets of SREBP-1 and SREBP-2 involved in biosynthesis of fatty acid and cholesterol. Treatment of Caov-3, OVCA-432, and OVCAR-3 cells with LPA increased expression levels of FAS and ACC proteins as shown in Fig. 2A. The mRNA levels of these key enzymes for fatty acid synthesis (data not shown) and the rate-limiting enzyme for cholesterol synthesis HMG-CoA reductase were also significantly increased by treatment of ovarian cancer cell lines with LPA (Fig. 2B), providing evidence that activation of SREBP-1 and SREBP-2 by LPA is sufficient to increase expression of key endogenous lipogenic enzymes in ovarian cancer cells.

LPA Induces Dephosphorylation of AMPK and ACC—In addition to transcriptional up-regulation, the activity of ACC is inhibited by AMPK-mediated phosphorylation. AMPK, a highly conserved protein serine/threonine kinase, acts as an energy sensor and regulator of cellular metabolism, shutting down energy-consuming anabolic processes and activating energy-yielding catabolic processes (37). AMPK is activated through phosphorylation of Thr-172 within the activation domain of the α -subunit (38). To determine the effect of LPA on AMPK and its downstream target ACC, we analyzed the phosphorylation status of AMPK α at this residue as a surrogate of activation of the enzyme. Treatment of Caov-3 and OVCA-432 cells with LPA induced late onset and sustained dephosphorylation of AMPK α (Fig. 3). The decrease in AMPK α phosphorylation was detectable at 8 h and became prominent at 12 h. Consistent with a predominant role of AMPK α in phosphorylation of ACC, AMPK α dephosphorylation in LPA-




FIGURE 3. LPA induces dephosphorylation of AMPK α and ACC. Caov-3 and OVCA-432 cells were treated with or without LPA (10 μ M) for the indicated periods of time. The cell lysates were analyzed with immunoblotting for phosphorylation status of AMPK α and ACC using their phospho-specific antibodies recognizing AMPK α phosphorylated at Thr-172 or ACC phosphorylated at Ser-79.

treated cells was accompanied by a decrease in ACC phosphorylation at Ser-79 (Fig. 3). Dephosphorylation of this site is known to enhance ACC enzymatic activity. The effects of LPA on dephosphorylation of AMPK α and ACC were not detected in IOSE-29 cells (data not shown). These results establish that LPA signaling is coupled to activation of ACC via inhibition of AMPK.

LPA Promotes de Novo Lipid Synthesis—Few studies have examined the role of exogenous factors in regulation of lipogenesis in cancer cells (5, 39). We examined whether LPA-induced activation of lipogenic enzymes is functionally sufficient to stimulate *de novo* lipid synthesis. The ovarian cancer cell lines Caov-3 and OVCA-432 and the immortalized IOSE-29 cells were treated with LPA or BSA as vehicle control and pulse-labeled with [14 C]acetic acid to monitor the amount of new lipid synthesis. As demonstrated in Fig. 4A (left panel), LPA treatment led to a significant increase in 14 C incorporation into the cellular lipid fractions, reflecting an increase in newly synthesized lipids in response to LPA. The lipogenic effect of LPA was specifically detected in multiple ovarian cancer cell lines but not in the nontransformed IOSE-29 cells, wherein LPA failed to induce SREBP activation or AMPK dephosphorylation. Because these cells were treated with LPA in serum-free medium lacking extracellular fatty acids, we wanted to determine whether the increase in lipogenesis in response to LPA is influenced by availability of extracellular lipids. As shown in Fig. 4A (right panel), exogenously supplemented palmitate slightly reduced LPA-driven lipogenesis. The reduction was, however, statistically insignificant, indicating that the lipogenic role of LPA is largely independent of availability of extracellular fatty acids. Consistent with the pro-lipogenic action of LPA, staining with the lipophilic dye BODIPY 493/503 revealed that LPA induced moderate increases in the intracellular contents of neutral lipids in Caov-3 and OVCA-432 cells but not in IOSE-29 cells (Fig. 4B). These results were further supported by the increases in both cellular TAG and phospholipids following LPA treatment (Fig. 4, C and D).

LPA $_2$ Is Major Receptor Subtype Responsible for Regulation of SREBP and AMPK—Caov-3, OVCA-432, and other ovarian cancer cell lines express the Edg LPA receptors LPA $_1$, LPA $_2$, and LPA $_3$ (Fig. 5A). The other non-Edg LPA receptors are




FIGURE 4. LPA stimulates *de novo* lipid synthesis. Caov-3, OVCA-432, and IOSE-29 cells were treated with LPA (10 μ M) or BSA (vehicle) for 24 h. In the last 6 h of incubation, the cells were pulse-labeled with 5 μ Ci/ml of [¹⁴C]acetic acid before lipid extraction as described under "Experimental Procedures." The incorporation of [¹⁴C] into lipid fractions was determined by scintillation counting. The results were presented as counts/min per 1×10^6 cells (A, left panel). Caov-3 and OVCA-432 cells were treated with LPA in serum-free medium supplemented with palmitate (10 μ M) and BSA (0.01%). LPA-induced lipogenesis was measured as described above (A, right panel). B, the parallel cells in 6-well plates were stained with BODIPY 493/503 fluorescent dye (0.5 μ g/ml) for 30 min, followed by staining with Hoechst (10 μ g/ml) for 15 min to monitor lipid accumulation. Shown were fluorescence microscopic photographs of IOSE-29, Caov-3, and OVCA-432 cells treated with or without LPA ($\times 80$ magnification). Total TAG (C) and phospholipids (D) in control and LPA-treated Caov-3 and OVCA-432 cells were determined as described under "Experimental Procedures." The results are presented as amounts of lipids per well or normalized on cell numbers to represent amounts of lipids per million cells.

either absent or expressed inconsistently in ovarian cancer cells (40, 41). Thus, we focused on the potential role of LPA₁₋₃ in the regulation of lipogenesis. We used siRNA to knock down expression of LPA₁, LPA₂, and LPA₃ in Caov-3 cells and examined SREBP activation and AMPK α dephosphorylation in response to LPA treatment. Interestingly, only knockdown of LPA₂ remarkably attenuated LPA-induced cleavage of SREBP-1, dephosphorylation of AMPK α at Thr-172 (Fig. 5B), as well as expression of FAS and ACC (Fig. 5C). There were little inhibitory effects on SREBP-1 activation, AMPK α dephosphorylation, and expression of FAS and ACC in conjunction with LPA₁ or LPA₃ knockdown. We encountered a technical difficulty in achieving efficient knockdown of LPA receptors with transient siRNA in OVCA-432 cells. However, similar results were obtained from OVCA-432 cells when LPA receptors were stably knocked down by lentivirus-transduced shRNA (Fig. 5, B and C). These results support a primary role of the LPA₂ receptor in LPA-dependent activation of SREBP-1 and inhibition of AMPK α . However, overexpression of LPA₂ in IOSE-29 cells was not sufficient to activate LPA-dependent

induction of FAS and ACC (data not shown), suggesting that additional signaling player(s) present specifically in malignant cells is involved.

To verify this receptor subtype-specific regulation of lipogenesis, we examined the effect of LPA₂ knockdown on LPA-driven lipogenesis. The *de novo* lipid synthesis in LPA receptor knockdown and control cells was assessed as described earlier. The endogenous lipid synthesis induced by LPA was strongly attenuated by siRNA- or shRNA-mediated down-regulation of LPA₂ (Fig. 5D). In contrast, knockdown of LPA₃ (Fig. 5D) or LPA₁ (data not shown) did not inhibit LPA-induced lipid synthesis.

LPA₂ Signaling Bifurcates to Regulate SREBP-1 and AMPK α —We next examined the signaling effectors downstream of LPA₂ responsible for cleavage of SREBP-1 and dephosphorylation of AMPK α . The LPA₁₋₃ receptors couple to G_i and G_q, whereas only LPA₁ and LPA₂ couple to G_{12/13} (42). We transfected dominant negative forms of these G proteins into highly transfectable Caov-3 cells in an effort to screen for G proteins critical for LPA-dependent SREBP-1 cleavage and AMPK α dephosphory-




FIGURE 5. LPA₂ mediates the lipogenic effect of LPA. Expression of mRNAs of LPA₁₋₃ receptors in IOSE-29, Caov-3, and OVCA-432 cells was determined by qPCR analysis as detailed under "Experimental Procedures" (A). The results were presented as fold difference relative to the mRNA levels of LPA receptors in IOSE-29 cells (defined as 1). Caov-3 cells were transfected with siRNA for each LPA receptor (LPA₁si, LPA₂si, and LPA₃si) or with nontargeting control siRNA (Csi). Expression of each LPA receptor in OVCA-432 cells was down-regulated by lentivirus-transduced shRNA. The knockdown efficiencies for each LPA receptor in both cell lines range from 60 to 80% as determined by qPCR analysis (data not shown). The cells were stimulated with LPA (10 μ M) for 12 h before immunoblotting analysis of SREBP-1 and phospho-AMPK α (B). *p*, precursor; *m*, active/mature. C, effects of LPA₂ knockdown on FAS and ACC induction in Caov-3 and OVCA-432 cells were examined by immunoblotting analysis. D, effects on lipid synthesis of siRNA or shRNA knockdown of LPA₁, LPA₂, or LPA₃ receptor in Caov-3 and OVCA-432 cells were measured as described in Fig. 4A.

lation. As shown in Fig. 6A, expression of the dominant negative G₁₂ attenuated LPA-induced SREBP-1 cleavage but not LPA-induced dephosphorylation of AMPK α . In contrast, expression of dominant negative G_q inhibited AMPK α dephosphorylation but not SREBP-1 cleavage induced by LPA. Thus,

different G protein cascades are implicated in the regulation of SREBP and AMPK by LPA. Because a prominent effector of G_{12/13} is the Rho GTPase, we examined whether Rho is required for LPA activation of SREBP. As expected, expression of dominant negative Rho (N19Rho) or the botulinum toxin C3,




FIGURE 6. LPA regulates SREBP and AMPK through different G protein cascades. Caov-3 cells were transfected to express dominant negative forms of G_i , G_q , and G_{12} or the control vector. The transfected cells were treated with LPA (10 μ M) for 12 h before immunoblotting analysis of SREBP-1 cleavage and AMPK α dephosphorylation (A). p, precursor; m, active/mature. B, dominant negative Rho (N19Rho) or C3 toxin expression vector was transfected into Caov-3 and OVCA-432 cells. The effects of N19Rho and C3 toxin on LPA-induced SREBP-1 cleavage were analyzed by immunoblotting. C, Caov-3 and OVCA-432 cells were treated with LPA in the presence of the PLC inhibitor U73122 or its inactive analog U73433 (10 μ M). LPA-induced AMPK α dephosphorylation was analyzed by immunoblotting.

a specific inhibitor of Rho GTPase, suppressed LPA-induced cleavage of SREBP-1 (Fig. 6B) as compared with vector-transfected cells. The results demonstrate that LPA₂ promotes SREBP activation in a Rho-dependent pathway.

To elucidate the regulatory network leading to AMPK dephosphorylation, we used pharmacological inhibitors of signaling molecules downstream of G_q . As shown in Fig. 6C, the PLC inhibitor U73122 but not its inactive analog U73433 blocked AMPK α dephosphorylation induced by LPA. The data support a G_q -PLC-dependent mechanism to control phosphorylation and activity of AMPK α in LPA-treated cells.

LPA-driven Cell Proliferation Requires LPA₂ and de Novo Lipid Synthesis—LPA is a mitogen that stimulates proliferation of ovarian cancer cells (43–46). To understand the biological significance of LPA-induced lipogenesis, we examined whether the pro-lipogenic activity of LPA contributes to LPA-driven proliferation of ovarian cancer cells. C75 and TOFA are well characterized specific inhibitors of FAS and ACC, respectively (47, 48). The presence of C75 dramatically decreased cell numbers of Caov-3 and OVCA-432 cells in serum-free medium supplemented with LPA as a growth factor (Fig. 7A), suggesting that the blockade of *de novo* lipogenesis could attenuate LPA-induced cell proliferation. Similar effects were observed in the presence of the ACC inhibitor TOFA (data not shown). At the concentrations we used, C75 and TOFA did not induce significant increases in apoptosis or appreciable decreases in cell viability (data not shown), suggesting that these inhibitors mainly targeted cell proliferation rather than cell survival. We also tested if exogenously added palmitate could reverse the effect of C75 on LPA-induced cell proliferation. At 10 μ M, palmitate partially prevented the effect of C75 (Fig. 7B). This ability of palmitate, however, was not seen at 20 μ M, suggesting possible cytotoxic effect of high concentrations of palmitate.

To obtain molecular evidence for involvement of FAS in LPA-induced cell proliferation, we used siRNA to knock down FAS expression in Caov-3 and OVCA-432 cells. Down-regulation of FAS expression indeed prevented proliferation of these cells induced by LPA (Fig. 7C). Finally, because LPA₂ is the key receptor subtype required for LPA activation of lipogenesis, we knocked down its expression to determine whether LPA₂ is an integral component of LPA-induced cell proliferation. As shown in Fig. 7D, following down-regulation of LPA₂, both cell lines exhibited significant decrease in growth rate when the cells were incubated in serum-free medium containing LPA. Thus LPA₂ and its associated lipogenesis-promoting activity are critical for LPA-induced cell proliferation.

DISCUSSION

The majority of the adult tissues depends on dietary fat to meet their nutritional needs. In contrast, cancer cells depend on *de novo* lipid synthesis for generation of fatty acids, irrespective of the available extracellular supplies. Malignant cells typically show a high rate of *de novo* fatty acid synthesis (49, 50). Intracellular fatty acids in rapidly dividing cancer cells not only supply energy through β -oxidation but more importantly serve as precursors for biosynthesis of membrane phospholipids, signaling lipids, and secondary messengers (51). The lipogenic phenotype of cancer cells has been primarily attributed to




FIGURE 7. LPA₂ and associated lipogenic activity are required for LPA-induced cell proliferation. Caov-3 and OVCA-432 cells in 6-well plates were incubated for 48 h in serum-free medium supplemented with 10 μ M LPA in the presence of indicated concentrations of the FAS inhibitor C75 (A). B, Caov-3 and OVCA-432 cells were incubated with LPA (10 μ M) and C75 in the presence of the indicated concentrations of palmitate. BSA was kept at a final concentration of 0.01% for all treatments. C and D, expression of FAS (C) or LPA₂ (D) was down-regulated by siRNA knockdown in Caov-3 and OVCA-432 cells to examine LPA-induced cell proliferation after 48 h of incubation with 10 μ M LPA. In all panels, cell numbers were quantitated with Coulter counter and presented as mean $\pm$ S.D. of triplicate assays, representative of three independent experiments.

increased expression or aberrant activity of the major lipogenic enzymes FAS and ACC. In particular, FAS, originally recognized as a tumor-specific antigen present in serum of cancer patients (34), is overexpressed in a variety of human malignancies. However, the cellular mechanisms by which lipogenic enzymes are up-regulated in cancer cells remain poorly understood except for a few studies suggesting that steroid hormones and Her family ligands could increase FAS expression via the PI3K or MAPK pathways (52–55).

In this study, we describe a novel LPA-mediated mechanism activating *de novo* lipogenesis in ovarian cancer cells. We demonstrated that treatment of ovarian cancer cell lines with LPA activates the SREBP-FAS and AMPK-ACC lipogenic cascades, culminating in increased *de novo* lipid synthesis. The lipogenic

effect of LPA was specifically observed in cancer cells as LPA failed to induce *de novo* lipogenesis in nontransformed IOSE-29 cells. LPA has been long known as a mediator of ovarian cancer. It is present at high concentrations in tumor microenvironments such as ascites of ovarian cancer patients and other malignant effusions (12, 13). This study highlights the possibility that LPA is an etiological factor in tumor microenvironments to promote lipogenesis in ovarian cancer cells, although the effect of LPA in other cancer cells remains to be determined.

A significant finding of this study is the selective role of the LPA₂ receptor in LPA activation of the lipogenic pathways and LPA-driven lipogenesis. We and others have previously shown that LPA₂ and LPA₃ are overexpressed in significant fractions

of ovarian cancer and in most ovarian cancer cell lines (16, 46). LPA₁, which is expressed by both normal and malignant ovarian epithelial cells, is dispensable for the pro-lipogenic activity of LPA in ovarian cancer cells. It is somewhat surprising that in both Caov-3 and OVCA-432 cells, knockdown of LPA₃ slightly potentiated the lipogenic effect of LPA (Fig. 5D). The results imply that the crosstalk among co-expressed LPA receptors is important in the control of biological outcomes of LPA. The specific role of LPA₂ in the promotion of lipogenesis in tumor cells is consistent with the increased expression of this receptor in various malignancies (16, 56–58). Although LPA₁ and LPA₃ have also been reported to be up- or down-regulated in some cancers, overexpression of LPA₂ is most commonly seen in almost all cancer types examined (16, 56–58). There is also strong evidence from xenograft mouse models and transgenic mice that LPA₂ is more oncogenic compared with LPA₁ and LPA₃ (17, 59). The compelling evidence for the implication of LPA₂ as an oncogene stems from recent studies by Yun and co-workers (18, 60) who showed that LPA₂-deficient mice were more resistant to intestinal tumorigenesis induced by colitis or by ApcMin mutation. However, the molecular mechanisms for the oncogenic activity of LPA₂ are not well understood. Most previous studies have been focused on the ability of LPA₂ to stimulate expression of oncogenic protein factors, including IL-6, VEGF, HIF1 α , c-Myc, cyclin D1, Kruppel-like factor 5, and Cox-2 (18, 32, 60–63). LPA₂ seems to be more potent than other LPA receptors in driving the transcriptional effects of LPA on these LPA target genes. This study links LPA₂ to the lipogenic phenotype of ovarian tumor cells. The role of LPA₂ in lipid metabolism provides a new avenue to explore the oncogenic role of LPA.

Different G proteins downstream of the LPA₂ receptor are involved in regulation of the SREBP-FAS and AMPK-ACC pathways in LPA-treated cells. Our results showed that SREBP cleavage/activation lies downstream of the G_{12/13}-Rho pathway, and AMPK dephosphorylation/inhibition is mediated by the G_q-PLC cascade. LPA stimulated cleavage of the precursor SREBP into mature and active forms in a time-dependent manner, which was accompanied by increases in SREBP-dependent transcriptional activity and up-regulation of endogenous SREBP target genes. In addition, the effect of LPA on SREBP cleavage and activation remains sensitive to cholesterol-mediated regulation, indicating the sterol-sensing machinery involved in SREBP cleavage is not disrupted by LPA. The proteolytic cleavage of SREBP is controlled by the combined action of SCAP and INSIG proteins (64). An increase in SCAP or a decrease in INSIG proteins could lead to activation of SREBP. Because androgens and insulin have been shown to regulate expression or stability of SCAP or INSIG (65, 66), it will be of interest to determine whether LPA modulates these proteins or their ratios to activate SREBP. This possibility is consistent with the observation that SREBP cleavage occurs hours after exposure of ovarian cancer cells to LPA.

It has yet to be determined how the G_q-PLC pathway is linked to dephosphorylation and inhibition of AMPK α . Obviously, our observation does not agree with Kim *et al.* (67), who recently reported that LPA stimulated transient phosphorylation of AMPK α at Thr-172 within the first 10 min of LPA treat-

ment in the SKOV-3 ovarian cancer cell line. In our experiments involving multiple ovarian cancer cell lines, there was little change in AMPK α phosphorylation status at the early time points. Instead, we observed a time-dependent decrease in phospho-AMPK α levels, which maximized after 12 h of incubation with LPA. The serine-threonine kinase LKB1, encoded by the Peutz-Jeghers syndrome tumor suppressor gene, is believed to be primary AMPK kinase as suggested by LKB1 knock-out studies (68–70). LKB1 possesses a nuclear localization domain and is located predominantly in the nucleus. Upon phosphorylation, LKB1 translocates to the cytoplasm where it forms an active complex with Ste20-related adaptor (STRAD) and mouse protein 25 (MO25) (71). LPA may down-regulate LKB1 activity via modulation of its phosphorylation, nuclear-cytoplasmic translocation, or association with STRAD-MO25 in the cytosol. In addition, AMPK phosphorylation could be down-regulated by inhibition of other candidate AMPK kinases such as calmodulin-dependent protein kinase kinase- β (71) or by activation of unknown AMPK phosphatase(s). A potential decrease in AMP/ATP ratio could also change the conformation of AMPK to prevent the active site (Thr-172) on the α -subunit from being exposed and phosphorylated by AMPK kinases.

Acknowledgment—Massey Cancer Center of Virginia Commonwealth University School of Medicine was recipient of National Institutes of Health Grant P30 CA16059.

REFERENCES

- Menendez, J. A., and Lupu, R. (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nat. Rev. Cancer* **7**, 763–777
- Wang, C., Rajput, S., Watabe, K., Liao, D. F., and Cao, D. (2010) Acetyl-CoA carboxylase-A as a novel target for cancer therapy. *Front. Biosci. (Schol. Ed.)* **2**, 515–526
- Gansler, T. S., Hardman, W., 3rd, Hunt, D. A., Schaffel, S., and Hennigar, R. A. (1997) Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. *Hum. Pathol.* **28**, 686–692
- Kuhajda, F. P., Piantadosi, S., and Pasternack, G. R. (1989) Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. *N. Engl. J. Med.* **321**, 636–641
- Kumar-Sinha, C., Ignatoski, K. W., Lippman, M. E., Ethier, S. P., and Chinnaiyan, A. M. (2003) Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. *Cancer Res.* **63**, 132–139
- Li, J. N., Gorospe, M., Chrest, F. J., Kumaravel, T. S., Evans, M. K., Han, W. F., and Pizer, E. S. (2001) Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. *Cancer Res.* **61**, 1493–1499
- Pizer, E. S., Thupari, J., Han, W. F., Pinn, M. L., Chrest, F. J., Frehywot, G. L., Townsend, C. A., and Kuhajda, F. P. (2000) Malonyl-coenzyme A is a potential mediator of cytotoxicity induced by fatty acid synthase inhibition in human breast cancer cells and xenografts. *Cancer Res.* **60**, 213–218
- Zhou, W., Simpson, P. J., McFadden, J. M., Townsend, C. A., Medghalchi, S. M., Vadlamudi, A., Pinn, M. L., Ronnett, G. V., and Kuhajda, F. P. (2003) Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. *Cancer Res.* **63**, 7330–7337
- Menendez, J. A., Colomer, R., and Lupu, R. (2004) Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. *Oncol. Rep.* **12**, 411–422
- Little, J. L., Wheeler, F. B., Fels, D. R., Koumenis, C., and Kridel, S. J. (2007) Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. *Cancer Res.* **67**, 1262–1269
- Mills, G. B., and Moolenaar, W. H. (2003) The emerging role of lysophos-

- phatidic acid in cancer. *Nat. Rev. Cancer* **3**, 582–591
12. Baker, D. L., Morrison, P., Miller, B., Riely, C. A., Tolley, B., Westermann, A. M., Bonfrer, J. M., Bais, E., Moolenaar, W. H., and Tigyi, G. (2002) Plasma lysophosphatidic acid concentration and ovarian cancer. *JAMA* **287**, 3081–3082
 13. Westermann, A. M., Havik, E., Postma, F. R., Beijnen, J. H., Dalesio, O., Moolenaar, W. H., and Rodenhuis, S. (1998) Malignant effusions contain lysophosphatidic acid (LPA)-like activity. *Ann. Oncol.* **9**, 437–442
 14. Choi, J. W., Herr, D. R., Noguchi, K., Yung, Y. C., Lee, C. W., Mutoh, T., Lin, M. E., Teo, S. T., Park, K. E., Mosley, A. N., and Chun, J. (2010) LPA receptors. Subtypes and biological actions. *Annu. Rev. Pharmacol. Toxicol.* **50**, 157–186
 15. Yanagida, K., Masago, K., Nakanishi, H., Kihara, Y., Hamano, F., Tajima, Y., Taguchi, R., Shimizu, T., and Ishii, S. (2009) Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. *J. Biol. Chem.* **284**, 17731–17741
 16. Fang, X., Schummer, M., Mao, M., Yu, S., Tabassam, F. H., Swaby, R., Hasegawa, Y., Tanyi, J. L., LaPushin, R., Eder, A., Jaffe, R., Erickson, J., and Mills, G. B. (2002) Lysophosphatidic acid is a bioactive mediator in ovarian cancer. *Biochim. Biophys. Acta* **1582**, 257–264
 17. Yu, S., Murph, M. M., Lu, Y., Liu, S., Hall, H. S., Liu, J., Stephens, C., Fang, X., and Mills, G. B. (2008) Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. *J. Natl. Cancer Inst.* **100**, 1630–1642
 18. Lin, S., Wang, D., Iyer, S., Ghaleb, A. M., Shim, H., Yang, V. W., Chun, J., and Yun, C. C. (2009) The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. *Gastroenterology* **136**, 1711–1720
 19. Ha, J., Daniel, S., Broyles, S. S., and Kim, K. H. (1994) Critical phosphorylation sites for acetyl-CoA carboxylase activity. *J. Biol. Chem.* **269**, 22162–22168
 20. Fang, X., Jin, X., Xu, H. J., Liu, L., Peng, H. Q., Hogg, D., Roth, J. A., Yu, Y., Xu, F., Bast, R. C., Jr., and Mills, G. B. (1998) Expression of p16 induces transcriptional down-regulation of the RB gene. *Oncogene* **16**, 1–8
 21. Maines-Bandiera, S. L., Kruk, P. A., and Auersperg, N. (1992) Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. *Am. J. Obstet. Gynecol.* **167**, 729–735
 22. Chen, H., Wu, X., Pan, Z. K., and Huang, S. (2010) Integrity of SOS1/EPS8/AB11 tri-complex determines ovarian cancer metastasis. *Cancer Res.* **70**, 9979–9990
 23. Dent, P., Han, S. I., Mitchell, C., Studer, E., Yacoub, A., Grandis, J., Grant, S., Krystal, G. W., and Hylemon, P. B. (2005) Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes. *Biochem. Pharmacol.* **70**, 1685–1696
 24. Dent, P., Fang, Y., Gupta, S., Studer, E., Mitchell, C., Spiegel, S., and Hylemon, P. B. (2005) Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes. *Hepatology* **42**, 1291–1299
 25. Soede, R. D., Wijnands, Y. M., Kamp, M., van der Valk, M. A., and Roos, E. (2000) G_i and G_{q/11} proteins are involved in dissemination of myeloid leukemia cells to the liver and spleen, whereas bone marrow colonization involves G_{q/11} but not G_i. *Blood* **96**, 691–698
 26. Stanners, J., Kabouridis, P. S., McGuire, K. L., and Tsoukas, C. D. (1995) Interaction between G proteins and tyrosine kinases upon T cell receptor. CD3-mediated signaling. *J. Biol. Chem.* **270**, 30635–30642
 27. Gohla, A., Offermanns, S., Wilkie, T. M., and Schultz, G. (1999) Differential involvement of G_{α12} and G_{α13} in receptor-mediated stress fiber formation. *J. Biol. Chem.* **274**, 17901–17907
 28. Aktories, K., and Hall, A. (1989) Botulinum ADP-ribosyltransferase C3. A new tool to study low molecular weight GTP-binding proteins. *Trends Pharmacol. Sci.* **10**, 415–418
 29. Song, Y., Wu, J., Oyesanya, R. A., Lee, Z., Mukherjee, A., and Fang, X. (2009) Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. *Clin. Cancer Res.* **15**, 492–501
 30. Briggs, M. R., Yokoyama, C., Wang, X., Brown, M. S., and Goldstein, J. L. (1993) Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification of the protein and delineation of its target nucleotide sequence. *J. Biol. Chem.* **268**, 14490–14496
 31. Chatterjee, S., Szustakowski, J. D., Nangneri, N. R., Mickanin, C., Labow, M. A., Nohturfft, A., Dev, K. K., and Sivasankaran, R. (2009) Identification of novel genes and pathways regulating SREBP transcriptional activity. *PLoS One* **4**, e5197
 32. Fang, X., Yu, S., Bast, R. C., Liu, S., Xu, H. J., Hu, S. X., LaPushin, R., Claret, F. X., Aggarwal, B. B., Lu, Y., and Mills, G. B. (2004) Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. *J. Biol. Chem.* **279**, 9653–9661
 33. Lee, Z., Swaby, R. F., Liang, Y., Yu, S., Liu, S., Lu, K. H., Bast, R. C., Jr., Mills, G. B., and Fang, X. (2006) Lysophosphatidic acid is a major regulator of growth-regulated oncogene α in ovarian cancer. *Cancer Res.* **66**, 2740–2748
 34. Kuhajda, F. P. (2000) Fatty-acid synthase and human cancer. New perspectives on its role in tumor biology. *Nutrition* **16**, 202–208
 35. Brown, M. S., and Goldstein, J. L. (1997) The SREBP pathway. Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. *Cell* **89**, 331–340
 36. Yang, T., Espenshade, P. J., Wright, M. E., Yabe, D., Gong, Y., Aebersold, R., Goldstein, J. L., and Brown, M. S. (2002) Crucial step in cholesterol homeostasis. Sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. *Cell* **110**, 489–500
 37. Hardie, D. G. (2007) AMP-activated/SNF1 protein kinases. Conserved guardians of cellular energy. *Nat. Rev. Mol. Cell Biol.* **8**, 774–785
 38. Hawley, S. A., Davison, M., Woods, A., Davies, S. P., Beri, R. K., Carling, D., and Hardie, D. G. (1996) Characterization of the AMP-activated protein kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. *J. Biol. Chem.* **271**, 27879–27887
 39. Swinnen, J. V., Heemers, H., Deboel, L., Foulfelle, F., Heyns, W., and Verhoeven, G. (2000) Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. *Oncogene* **19**, 5173–5181
 40. Oyesanya, R. A., Lee, Z. P., Wu, J., Chen, J., Song, Y., Mukherjee, A., Dent, P., Kordula, T., Zhou, H., and Fang, X. (2008) Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells. *FASEB J.* **22**, 2639–2651
 41. Kishi, Y., Okudaira, S., Tanaka, M., Hama, K., Shida, D., Kitayama, J., Yamori, T., Aoki, J., Fujimaki, T., and Arai, H. (2006) Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. *J. Biol. Chem.* **281**, 17492–17500
 42. Noguchi, K., Herr, D., Mutoh, T., and Chun, J. (2009) Lysophosphatidic acid (LPA) and its receptors. *Curr. Opin. Pharmacol.* **9**, 15–23
 43. Kamrava, M., Simpkins, F., Alejandro, E., Michener, C., Meltzer, E., and Kohn, E. C. (2005) Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulysin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer. *Oncogene* **24**, 7084–7093
 44. Goldsmith, Z. G., Ha, J. H., Jayaraman, M., and Dhanasekaran, D. N. (2011) Lysophosphatidic acid stimulates the proliferation of ovarian cancer cells via the GEP Proto-oncogene G α_{12} . *Genes Cancer* **2**, 563–575
 45. Pua, T. L., Wang, F. Q., and Fishman, D. A. (2009) Roles of LPA in ovarian cancer development and progression. *Future Oncol.* **5**, 1659–1673
 46. Goetzl, E. J., Dolezalova, H., Kong, Y., Hu, Y. L., Jaffe, R. B., Kalli, K. R., and Conover, C. A. (1999) Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. *Cancer Res.* **59**, 5370–5375
 47. Halvorson, D. L., and McCune, S. A. (1984) Inhibition of fatty acid synthesis in isolated adipocytes by 5-(tetradecyloxy)-2-furoic acid. *Lipids* **19**, 851–856
 48. Kuhajda, F. P., Pizer, E. S., Li, J. N., Mani, N. S., Frehywot, G. L., and Townsend, C. A. (2000) Synthesis and antitumor activity of an inhibitor of fatty acid synthase. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 3450–3454
 49. Ookhtens, M., Kannan, R., Lyon, I., and Baker, N. (1984) Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. *Am. J.*

- Physiol.* **247**, R146–R153
50. Rashid, A., Pizer, E. S., Moga, M., Milgraum, L. Z., Zahurak, M., Pasternack, G. R., Kuhajda, F. P., and Hamilton, S. R. (1997) Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. *Am. J. Pathol.* **150**, 201–208
 51. Swinnen, J. V., Brusselmans, K., and Verhoeven, G. (2006) Increased lipogenesis in cancer cells. New players, novel targets. *Curr. Opin. Clin. Nutr. Metab. Care* **9**, 358–365
 52. Yang, Y. A., Han, W. F., Morin, P. J., Chrest, F. J., and Pizer, E. S. (2002) Activation of fatty acid synthesis during neoplastic transformation. Role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. *Exp. Cell Res.* **279**, 80–90
 53. Van de Sande, T., De Schrijver, E., Heyns, W., Verhoeven, G., and Swinnen, J. V. (2002) Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. *Cancer Res.* **62**, 642–646
 54. Swinnen, J. V., Esquenet, M., Goossens, K., Heyns, W., and Verhoeven, G. (1997) Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. *Cancer Res.* **57**, 1086–1090
 55. Menendez, J. A., Oza, B. P., Colomer, R., and Lupu, R. (2005) The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. *Int. J. Oncol.* **26**, 1507–1515
 56. Shida, D., Watanabe, T., Aoki, J., Hama, K., Kitayama, J., Sonoda, H., Kishi, Y., Yamaguchi, H., Sasaki, S., Sako, A., Konishi, T., Arai, H., and Nagawa, H. (2004) Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. *Lab. Invest.* **84**, 1352–1362
 57. Schulte, K. M., Beyer, A., Köhrer, K., Oberhäuser, S., and Röher, H. D. (2001) Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells. Overexpression of the high affinity receptor *edg4* in differentiated thyroid cancer. *Int. J. Cancer* **92**, 249–256
 58. Kitayama, J., Shida, D., Sako, A., Ishikawa, M., Hama, K., Aoki, J., Arai, H., and Nagawa, H. (2004) Overexpression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. *Breast Cancer Res.* **6**, R640–R646
 59. Liu, S., Umezū-Goto, M., Murph, M., Lu, Y., Liu, W., Zhang, F., Yu, S., Stephens, L. C., Cui, X., Murrow, G., Coombes, K., Muller, W., Hung, M. C., Perou, C. M., Lee, A. V., Fang, X., and Mills, G. B. (2009) Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. *Cancer Cell* **15**, 539–550
 60. Lin, S., Lee, S. J., Shim, H., Chun, J., and Yun, C. C. (2010) The absence of LPA receptor 2 reduces the tumorigenesis by ApcMin mutation in the intestine. *Am. J. Physiol. Gastrointest. Liver Physiol.* **299**, G1128–G1138
 61. Jeong, K. J., Park, S. Y., Seo, J. H., Lee, K. B., Choi, W. S., Han, J. W., Kang, J. K., Park, C. G., Kim, Y. K., and Lee, H. Y. (2008) Lysophosphatidic acid receptor 2 and G_i/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells. *Exp. Mol. Med.* **40**, 607–616
 62. Zhao, Y., Tong, J., He, D., Pendyala, S., Evgeny, B., Chun, J., Sperling, A. I., and Natarajan, V. (2009) Role of lysophosphatidic acid receptor LPA2 in the development of allergic airway inflammation in a murine model of asthma. *Respir. Res.* **10**, 114
 63. Huang, M. C., Lee, H. Y., Yeh, C. C., Kong, Y., Zaloudek, C. J., and Goetzl, E. J. (2004) Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2). *Oncogene* **23**, 122–129
 64. Rawson, R. B. (2003) The SREBP pathway. Insights from insects. *Nat. Rev. Mol. Cell Biol.* **4**, 631–640
 65. Heemers, H., Maes, B., Foufelle, F., Heyns, W., Verhoeven, G., and Swinnen, J. V. (2001) Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage-activating protein/sterol regulatory element-binding protein pathway. *Mol. Endocrinol.* **15**, 1817–1828
 66. Yellaturu, C. R., Deng, X., Park, E. A., Raghoebar, R., and Elam, M. B. (2009) Insulin enhances the biogenesis of nuclear sterol regulatory element-binding protein (SREBP)-1c by post-transcriptional down-regulation of Insig-2A and its dissociation from SREBP cleavage-activating protein (SCAP)-SREBP-1c complex. *J. Biol. Chem.* **284**, 31726–31734
 67. Kim, E. K., Park, J. M., Lim, S., Choi, J. W., Kim, H. S., Seok, H., Seo, J. K., Oh, K., Lee, D. S., Kim, K. T., Ryu, S. H., and Suh, P. G. (2011) Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells. *J. Biol. Chem.* **286**, 24036–24045
 68. Sakamoto, K., McCarthy, A., Smith, D., Green, K. A., Grahame Hardie, D., Ashworth, A., and Alessi, D. R. (2005) Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. *EMBO J.* **24**, 1810–1820
 69. Sakamoto, K., Zarrinpashneh, E., Budas, G. R., Pouleur, A. C., Dutta, A., Prescott, A. R., Vanoverschelde, J. L., Ashworth, A., Jovanović, A., Alessi, D. R., and Bertrand, L. (2006) Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPK α 2 but not AMPK α 1. *Am. J. Physiol. Endocrinol. Metab.* **290**, E780–E788
 70. Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S. H., Bardeesy, N., Depinho, R. A., Montminy, M., and Cantley, L. C. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. *Science* **310**, 1642–1646
 71. Shackelford, D. B., and Shaw, R. J. (2009) The LKB1-AMPK pathway. Metabolism and growth control in tumor suppression. *Nat. Rev. Cancer* **9**, 563–575